Key partners add to growing list of academic institutions making reagents available

Kerafast Inc., developers of an online platform to facilitate accessibility to unique bioresearch materials from laboratories across the globe, today announced an increase in the number of international institutional laboratories adding reagents and services to its catalog.  Kerafast now offers reagents and services from 142 partnering academic research institutions, of which 14% are located outside the United States.  Recent international institutions to have joined the program include from Israel, Ramot - Tel Aviv University's business engagement center; from Canada, the University of Calgary and Dalhousie University; the University of Göttingen Medical Center in Germany, the University of Oslo in Norway, and Flinders University in Australia.

“Kerafast promotes access to rare and unique research reagents and helps to facilitate a community of both Providing and Procuring laboratories that work toward the cure of disease,” said Dr. Jennifer Rossi, Kerafast’s Chief Operating Officer.  “We are pleased to add more international academic institutions to broaden our portfolio and help to disseminate research materials.”

These new international partnerships add a variety of unique products to Kerafast’s catalog including complement antibodies, reversible streptavidin protein, carboxypeptidase antibody, zebrafish circadian clock model services and cancer angiogenesis services.

Since its founding in late 2011, Kerafast’s catalog has grown to more than 2,600 products.  Through the company’s efforts, many rare and unique research materials previously hidden in laboratory freezers have been made available to scientists worldwide via a straightforward research use only “click license”. Kerafast plans to continue its European and Asia-Pacific expansion over the coming year.

About Kerafast, Inc.

Kerafast has partnered with >140 prominent academic research institutions internationally that provide thousands of rare and unique ‘Reagents for the Greater Good’ for the benefit of the scientific community working toward the cure of disease in 52 countries on 6 continents.

Find out more